Aoxing Pharma gets clinical trial approval for Buprenorphine/Naloxone tablets
Aoxing Pharmaceutical announced that the China SFDA has granted approval of the company's New Drug Application to initiate the registration clinical trial of Buprenorphine/Naloxone sublingual tablets for opioid addiction treatment. The approval enables Aoxing Pharma to move forward to the final development stage with this therapy, which is novel in China as it is not yet available to patients. :theflyonthewall.com
News For AXN From The Last 14 Days
Check below for free stories on AXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
